163 related articles for article (PubMed ID: 20821397)
1. Risk assessment and physicochemical characterization of a metastable dihydrate API phase for intravenous formulation development.
Mortko CJ; Sheth AR; Variankaval N; Li L; Farrer BT
J Pharm Sci; 2010 Dec; 99(12):4973-81. PubMed ID: 20821397
[TBL] [Abstract][Full Text] [Related]
2. Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API.
McNamara DP; Childs SL; Giordano J; Iarriccio A; Cassidy J; Shet MS; Mannion R; O'Donnell E; Park A
Pharm Res; 2006 Aug; 23(8):1888-97. PubMed ID: 16832611
[TBL] [Abstract][Full Text] [Related]
3. Application of melt extrusion in the development of a physically and chemically stable high-energy amorphous solid dispersion of a poorly water-soluble drug.
Lakshman JP; Cao Y; Kowalski J; Serajuddin AT
Mol Pharm; 2008; 5(6):994-1002. PubMed ID: 19434852
[TBL] [Abstract][Full Text] [Related]
4. Aqueous solubility of crystalline and amorphous drugs: Challenges in measurement.
Murdande SB; Pikal MJ; Shanker RM; Bogner RH
Pharm Dev Technol; 2011 Jun; 16(3):187-200. PubMed ID: 20429826
[TBL] [Abstract][Full Text] [Related]
5. Rapid conversion of API hydrates to anhydrous forms in aqueous media.
Petrova RI; Peresypkin A; Mortko CJ; McKeown AE; Lee J; Williams JM
J Pharm Sci; 2009 Nov; 98(11):4111-8. PubMed ID: 19384923
[TBL] [Abstract][Full Text] [Related]
6. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
[TBL] [Abstract][Full Text] [Related]
7. Drug-polymer solubility and miscibility: Stability consideration and practical challenges in amorphous solid dispersion development.
Qian F; Huang J; Hussain MA
J Pharm Sci; 2010 Jul; 99(7):2941-7. PubMed ID: 20127825
[TBL] [Abstract][Full Text] [Related]
8. Methodology for phase selection of a weak basic drug candidate, utilizing kinetic solubility profiles in bio-relevant media.
Furukawa S; Zhao C; Ohki Y
Eur J Pharm Biopharm; 2010 Feb; 74(2):298-303. PubMed ID: 19815062
[TBL] [Abstract][Full Text] [Related]
9. Drug polymorphism and dosage form design: a practical perspective.
Singhal D; Curatolo W
Adv Drug Deliv Rev; 2004 Feb; 56(3):335-47. PubMed ID: 14962585
[TBL] [Abstract][Full Text] [Related]
10. Development and validation of in silico models for estimating drug preformulation risk in PEG400/water and Tween80/water systems.
Crivori P; Morelli A; Pezzetta D; Rocchetti M; Poggesi I
Eur J Pharm Sci; 2007 Nov; 32(3):169-81. PubMed ID: 17714921
[TBL] [Abstract][Full Text] [Related]
11. Aqueous solubility: simple predictive methods (in silico, in vitro and bio-relevant approaches).
Elder D; Holm R
Int J Pharm; 2013 Aug; 453(1):3-11. PubMed ID: 23124107
[TBL] [Abstract][Full Text] [Related]
12. General principles of pharmaceutical solid polymorphism: a supramolecular perspective.
Rodríguez-Spong B; Price CP; Jayasankar A; Matzger AJ; Rodríguez-Hornedo N
Adv Drug Deliv Rev; 2004 Feb; 56(3):241-74. PubMed ID: 14962581
[TBL] [Abstract][Full Text] [Related]
13. [Polymorph transformation of solid drugs].
Zhang Q; Mei XF
Yao Xue Xue Bao; 2015 May; 50(5):521-7. PubMed ID: 26234130
[TBL] [Abstract][Full Text] [Related]
14. Nanosizing--oral formulation development and biopharmaceutical evaluation.
Kesisoglou F; Panmai S; Wu Y
Adv Drug Deliv Rev; 2007 Jul; 59(7):631-44. PubMed ID: 17601629
[TBL] [Abstract][Full Text] [Related]
15. Classification of solid dispersions: correlation to (i) stability and solubility (ii) preparation and characterization techniques.
Meng F; Gala U; Chauhan H
Drug Dev Ind Pharm; 2015; 41(9):1401-15. PubMed ID: 25853292
[TBL] [Abstract][Full Text] [Related]
16. Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement.
Löbmann K; Grohganz H; Laitinen R; Strachan C; Rades T
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):873-81. PubMed ID: 23537574
[TBL] [Abstract][Full Text] [Related]
17. Preformulation characterization and in vivo absorption in beagle dogs of JFD, a novel anti-obesity drug for oral delivery.
Fan Y; Yang M; Wang Y; Li Y; Zhou Y; Chen X; Shan L; Wei J; Gao C
Drug Dev Ind Pharm; 2015 May; 41(5):801-11. PubMed ID: 24694186
[TBL] [Abstract][Full Text] [Related]
18. Overview of drug product development.
Narayan P
Curr Protoc Pharmacol; 2011 Dec; Chapter 7():Unit 7.3.1-29. PubMed ID: 22147349
[TBL] [Abstract][Full Text] [Related]
19. Challenges in the development of hydrate phases as active pharmaceutical ingredients--an example.
Feth MP; Nagel N; Baumgartner B; Bröckelmann M; Rigal D; Otto B; Spitzenberg M; Schulz M; Becker B; Fischer F; Petzoldt C
Eur J Pharm Sci; 2011 Jan; 42(1-2):116-29. PubMed ID: 21073949
[TBL] [Abstract][Full Text] [Related]
20. Importance of early characterization of physicochemical properties in developing high-dose intravenous infusion regimens for poorly water-soluble compounds.
Jain A; Zheng W; Garad S; Weaver M; Panicucci R
PDA J Pharm Sci Technol; 2010; 64(6):517-26. PubMed ID: 21502062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
